pyrroles has been researched along with Synovioma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrari, S; Paioli, A; Palmerini, E | 1 |
| Buettner, R; Czerwitzki, J; Endl, E; Friedrichs, N; Hartmann, W; Heukamp, LC; Holst, MI; Kawai, A; Koch, A; Küchler, J; Larsson, O; Metzger, D; Pietsch, T; Schulte, JH; Tanaka, S; Wardelmann, E; Wurst, P | 1 |
| Aoyama, T; Ishibe, T; Katagiri, T; Nagayama, S; Nakamura, T; Nakamura, Y; Nakayama, T; Nishijo, K; Okamoto, T; Shibata, KR; Shima, Y; Toguchida, J | 1 |
| Kimura, T; Shimada, K; Ushiyama, S; Wada, Y | 1 |
| Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J | 1 |
1 review(s) available for pyrroles and Synovioma
| Article | Year |
|---|---|
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
4 other study(ies) available for pyrroles and Synovioma
| Article | Year |
|---|---|
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluorescent Antibody Technique; Humans; Insulin-Like Growth Factor II; Male; MAP Kinase Signaling System; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Synovial; Signal Transduction | 2008 |
Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Female; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Isoforms; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Synovial; Signal Transduction; Urea; Xenograft Model Antitumor Assays | 2005 |
Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW 982.
Topics: Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Dinoprostone; Humans; Interleukin-6; Interleukin-8; Matrix Metalloproteinase 13; Matrix Metalloproteinase Inhibitors; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Pyrroles; Sarcoma, Synovial; Spheroids, Cellular | 2005 |
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab | 2005 |